Use of clinical characteristics, cystoscopic findings, and urine biomarkers in predicting satisfactory treatment outcome in women with interstitial cystitis/bladder pain syndrome: A retrospective analysis

Purpose: Currently, there is no effective and durable treatment for all patients with interstitial cystitis/bladder pain syndrome (IC/BPS). It is possible that multiple pathophysiologies underlie this disease. This study investigated the association between clinical parameters and urine biomarkers and overall treatment outcomes in women with IC/BPS. Materials and methods: Women with IC/BPS were retrospectively included in this study. The clinical symptoms, videourodynamic study, cystoscopic features under anesthesia, and urinary inflammatory and oxidative stress biomarkers were investigated and compared between patients who were satisfactory or unsatisfactory to different bladder therapy for IC/BPS. The clinical parameters were searched for predicting a satisfactory treatment outcome. Results: A total of 315 IC/BPS patients including 291 non-Hunner IC (NHIC) and 24 Hunner IC were included, with a mean age of 53.3 ± 13.3 years and a median follow-up period of 10 years. Among the NHIC patients, 167 (57.4%) had a satisfactory outcome (GRA 2 or 3) after treatment. NHIC patients with a baseline larger maximal bladder capacity in hydrodistention and larger first sensation of filling in videourodynamic study predict a satisfactory outcome after different bladder therapy. The urinary levels of lower C-X-C motif chemokine ligand 10, 8-hydroxydeoxyguanosine, and 8-isoprostane also predict a satisfactory treatment outcome in patients with NHIC. Conclusion: The results of this study revealed that patients with NHIC and had a larger first sensation of filling, maximal bladder capacity, lower urinary levels of C-X-C motif chemokine ligand 10, 8-hydroxydeoxyguanosine, and 8-isoprostane might have a satisfactory outcome, indicating less bladder inflammation might have a better treatment result.